Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL [Phase 2]
A Phase 2 clinical trial examining Surovatamig (AZD0486) as monotherapy in relapsed/refractory B-cell non-Hodgkin lymphoma, including follic…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Long-term Follow up Local Registry Study of Kymriah in South Korea
This clinical trial update reports a long-term follow-up local registry study of Kymriah in South Korea. Recruitment is ongoing for patients…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CAR-20/19-T cells in relapsed or refractory B-cell malignancies, including multiple non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial is investigating LV20.19 CAR T-cells in combination with pirtobrutinib for relapsed or refractory B-cell malignanci…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of APG-3288 in Relapsed/Refractory Blood Cancers [Phase 1]
Phase 1 study of APG-3288 in relapsed/refractory hematologic cancers; the trial is not yet recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epco, Zanu, Ritux for R/R FL or MZL [Phase 2]
Phase 2 clinical trial recruiting to evaluate Epco, Zanu, and rituximab in relapsed/refractory follicular lymphoma and marginal zone lymphom…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A pharmacokinetic study is evaluating how crushing venetoclax tablets and dissolving them in solution affects drug exposure, to assess alter…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of Zanubrutinib, Rituximab, Lenalidomide (ZR²) in combination with Tislelizumab fo…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R [NA]
A single-arm, non-randomized pilot trial to evaluate the safety of autologous anti-CD19 CAR-T cells (ARI-0001) and the feasibility of local …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
A real-world study is evaluating subcutaneous epcoritamab in adults with diffuse large B-cell lymphoma and follicular lymphoma and is curren…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas [Phase 3]
This clinical trial update describes a Phase 3 study evaluating reduced-dose radiation therapy for people with B-cell lymphomas, specificall…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma [Phase 1, Phase 2]
This document reports an ongoing Phase 1/2 study evaluating tazemetostat with rituximab and abbreviated bendamustine as frontline therapy fo…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of SGR-1505 in Mature B-Cell Neoplasms [Phase 1]
Schrödinger's SGR-1505 is being evaluated in a Phase 1 trial across multiple mature B-cell neoplasms and is currently recruiting. The study …
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial from Mayo Clinic is evaluating BAFFR-based CAR-T cells with lymphodepletion (fludarabine and cyclophosphamide) for re…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial assessing the safety of LTZ-301 in patients with various forms of non-Hodgkin lymphoma, currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas [Phase 2]
A Phase 2 clinical trial evaluating the combination of acalabrutinib and obinutuzumab as initial therapy for previously untreated follicular…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma [Phase 3]
Phase 3 trial to compare odronextamab plus chemotherapy versus rituximab plus chemotherapy in adults with follicular lymphoma to assess safe…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas [Phase 2]
This Phase 2 clinical trial update describes evaluating rituximab in combination with zanubrutinib for indolent B-cell lymphomas, including …
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma [Phase 3]
Phase 3 study comparing mosunetuzumab plus lenalidomide to rituximab plus lenalidomide in relapsed or refractory follicular lymphoma, includ…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
This clinical trial update notes that mosunetuzumab is being evaluated in a compassionate-use program for relapsed/refractory follicular lym…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A clinical trial update describes EO2463, a novel vaccine, being studied as monotherapy and in combination for indolent non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Evaluate the Safety and Clinical Activity of HH2853 [Phase 1, Phase 2]
The trial update indicates HH2853 is being studied in Phase 1/Phase 2 across follicular lymphoma, epithelioid sarcoma, peripheral T-cell lym…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy [Phase 2]
A Phase 2 trial is evaluating whether vaccination with Prevnar 13 before and after CAR-T therapy can enhance cellular and humoral immunity i…